The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Non-profit
  • Books
  • Artificial Intelligence
  • Education
  • Automotive

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Obsolete Industrial Expands Its Membership
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Four-Time Olympian Joetta Clark Diggs to Compete at World Masters Athletics Championships in Daegu

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Kellyn Endorses National Push to Expand Food is Medicine
  • LATO AI Automates Customer Communication to Help CSide Sports Academy and BAT 24 Nation Grow
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Tina Hasselbusch, Turnstone Creative Co-founder and Chief Executive Officer, Named to LVB 300
  • Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
  • Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 681
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 108
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH - 102
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Crossroads4Hope Announces The Lipschutz Women's Fund

Similar on PennZone

  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Roohid Parast, J&J Scientist, Comments on New Psoriasis Biomarker Study
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us